CN103298481A - 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途 - Google Patents

用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途 Download PDF

Info

Publication number
CN103298481A
CN103298481A CN2011800552054A CN201180055205A CN103298481A CN 103298481 A CN103298481 A CN 103298481A CN 2011800552054 A CN2011800552054 A CN 2011800552054A CN 201180055205 A CN201180055205 A CN 201180055205A CN 103298481 A CN103298481 A CN 103298481A
Authority
CN
China
Prior art keywords
prolactin
prolactin receptor
treatment
patient
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800552054A
Other languages
English (en)
Chinese (zh)
Inventor
W.Y.陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolix Inc
Original Assignee
Oncolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolix Inc filed Critical Oncolix Inc
Priority to CN201610675696.7A priority Critical patent/CN106177915A/zh
Publication of CN103298481A publication Critical patent/CN103298481A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2011800552054A 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途 Pending CN103298481A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610675696.7A CN106177915A (zh) 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/948,329 US8648046B2 (en) 2009-02-26 2010-11-17 Compositions and methods for visualizing and eliminating cancer stem cells
US12/948329 2010-11-17
PCT/US2011/061040 WO2012068282A1 (en) 2010-11-17 2011-11-16 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610675696.7A Division CN106177915A (zh) 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途

Publications (1)

Publication Number Publication Date
CN103298481A true CN103298481A (zh) 2013-09-11

Family

ID=45349276

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800552054A Pending CN103298481A (zh) 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途
CN201610675696.7A Pending CN106177915A (zh) 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610675696.7A Pending CN106177915A (zh) 2010-11-17 2011-11-16 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途

Country Status (9)

Country Link
US (2) US8648046B2 (https=)
EP (1) EP2640412B1 (https=)
JP (3) JP6306886B2 (https=)
KR (1) KR20140009196A (https=)
CN (2) CN103298481A (https=)
AU (1) AU2011328935B2 (https=)
CA (1) CA2817846A1 (https=)
IL (1) IL226271A (https=)
WO (1) WO2012068282A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167750A2 (en) * 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
EP3707166A4 (en) * 2017-11-06 2021-11-24 Daniel J. Monticello CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN113956356B (zh) * 2021-10-27 2023-05-02 福州迈新生物技术开发有限公司 抗prl蛋白单克隆抗体、细胞系及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099003A2 (en) * 2009-02-26 2010-09-02 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
EP1079851B1 (en) * 1998-05-12 2007-07-04 Greenville Hospital System Use of anti-prolactin agents to treat cancer
EP2180054A1 (en) * 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1282642B1 (en) * 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CN100479863C (zh) * 2006-09-06 2009-04-22 中国医学科学院北京协和医院 Cofilin 1与癌症的紫杉烷类化疗药物耐药性的相关性
EP2094291A1 (en) * 2006-12-21 2009-09-02 Novo Nordisk A/S Dimeric prolactin receptor ligands
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099003A2 (en) * 2009-02-26 2010-09-02 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘冠媛: "紫杉醇治疗卵巢癌研究进展", 《国外医学肿瘤学分册》 *
苏燕: "人催乳素受体拮抗剂在乳腺肿瘤研究中的进展", 《中国新药杂志》 *

Also Published As

Publication number Publication date
JP2016029110A (ja) 2016-03-03
CN106177915A (zh) 2016-12-07
IL226271A (en) 2017-05-29
KR20140009196A (ko) 2014-01-22
JP2013544254A (ja) 2013-12-12
US8648046B2 (en) 2014-02-11
WO2012068282A1 (en) 2012-05-24
JP6306886B2 (ja) 2018-04-04
EP2640412B1 (en) 2017-08-02
IL226271A0 (en) 2013-07-31
AU2011328935B2 (en) 2016-08-11
EP2640412A1 (en) 2013-09-25
JP2018062527A (ja) 2018-04-19
AU2011328935A1 (en) 2013-05-30
US20130231286A1 (en) 2013-09-05
US20110065639A1 (en) 2011-03-17
CA2817846A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
EP2640412B1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
US8754035B2 (en) Compositions and methods for visualizing and eliminating cancer stem cells
KR20160053843A (ko) 헤지호그 경로 억제제를 사용하는 증식 질환의 치료 및 예후 관찰
EP3969000B1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
JP2011504361A (ja) 肝細胞癌細胞に特異的なペプチドおよびその適用
CN114746094A (zh) 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法
CN102134275B (zh) 表皮生长因子受体变异体
WO2021208787A1 (zh) 用于筛选药物的靶标多肽和筛选方法
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
EP4694911A2 (en) Administration of a beta-catenin antagonist and methods of use
JP7254020B2 (ja) 融合遺伝子を含有するがんを治療する方法
KR20200068272A (ko) PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
Hu Radioimmunoimaging of p21 (WAF-1/CIP-1) intracellular epitopes in breast cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189171

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130911

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1189171

Country of ref document: HK